E-ISSN 2231-3206 | ISSN 2320-4672
 

Original Research 


Comparative study of telmisartan and ramipril as an antihypertensive in mild to moderate hypertension

Mustafa Raja, Ajay Kumar Shukla, Rekha Mehani, Astha Agnihotri.

Cited by (2)

Abstract
Background: Hypertension has been termed the silent killer; an asymptomatic chronic disorder that, if undetected and untreated, silently damages the blood vessels, heart, brain, and kidneys. In India, hypertension is emerging as a major health problem and is more prevalent in urban than in rural subjects. Hypertension is directly responsible for 57% of all stroke deaths and 24% of all coronary heart disease deaths in India.

Aims and Objectives: To compare the efficacy of telmisartan and ramipril as an antihypertensive in mild to moderate hypertension.

Materials and Methods: This study was a hospital-based prospective, randomized, comparative, observational study conducted over a period of 1-year. For the purpose of this study, equal numbers of mild to moderate hypertensive patients were randomly allocated equally between two groups: one group on telmisartan and the other group on ramipril. Patients were assessed for the blood pressure (BP) reduction during follow-up period of 6-month.

Results: In both telmisartan and ramipril groups, there was a significant reduction of systolic BP (SBP), diastolic BP (DBP), and mean BP (MBP) from beginning to the end of study (P < 0.001). There was a significant difference in reduction of SBP and MBP during 4-12 weeks (P < 0.001) between telmisartan and ramipril group but no significant difference in the reduction of SBP and MBP in both drug groups was seen at the end of the study.

Conclusion: Both telmisartan and ramipril groups were similar and comparable with regards to their SBP and DBP. In both telmisartan and ramipril groups, there was a significant reduction of SBP, DBP, and MBP from beginning to the end of study (P < 0.001).

Key words: Hypertension; Angiotensin-converting Enzyme Inhibitors; Angiotensin Receptors Blockers; Renin-angiotensin System


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Mustafa Raja
Articles by Ajay Kumar Shukla
Articles by Rekha Mehani
Articles by Astha Agnihotri
on Google
on Google Scholar


REFERENCES
1. Victor RG, Kaplan NM. Systemic hypertension: Mechanisms and diagnosis. In: Braunwald E, Libby P, Bonow RO, Mann DL, Zipes DP, editors. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 8th ed. Philadelphia, PA: Saunders/ Elsevier; 2007:1035.
2. Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens. 2004;18(2):73-8. https://doi.org/10.1038/sj.jhh.1001633 [Pubmed]   
3. Victor RG, Kaplan NM. Systemic hypertension: Mechanisms and diagnosis. In: Braunwald E, Libby P, Bonow RO, Mann DL, Zipes DP, editors. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 8th ed. Philadelphia, PA: Saunders/ Elsevier; 2007. p. 1027-33.
4. Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, et al. Primary prevention of hypertension: Clinical and public health advisory from the National High Blood Pressure Education Program. JAMA. 2002;288(15):1882-8. https://doi.org/10.1001/jama.288.15.1882 [Pubmed]   
5. Kotchen TA. Hypertensive vascular disease. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson J, Loscalzo J, editors. Harrison's Principles of Internal Medicine. 19th ed. New York, NY: McGraw-Hill; 2015. p. 1622-3.
6. Franklin SS. Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance? Curr Hypertens Rep. 2000;2:253-9.
7. Gavras I, Gavras H. Angiotensin converting enzyme inhibitors. In: Weber MA, editor. Hypertension Medicine. Totowa, NJ: Humana Press; 2001. p. 321.
8. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986;77(6):1993-2000. https://doi.org/10.1172/JCI112528 [Pubmed]    [PMC Free Fulltext]   
9. White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: Impact on the early morning period. Am J Hypertens. 2004;17(4):347-53. https://doi.org/10.1016/j.amjhyper.2004.02.016 [Pubmed]   
10. Lacourcière Y, Krzesinski JM, White WB, Davidai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit. 2004;9(4):203-10. https://doi.org/10.1097/00126097-200408000-00005 [Pubmed]   
11. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgammamodulating activity. Hypertension. 2004;43(5):993-1002. https://doi.org/10.1161/01.HYP.0000123072.34629.57 [Pubmed]   
12. Hilal-Dandan R. Renin and angiotensin. In: Brunton LB, Chabner BA, Knollman BC, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011. p. 733-8.
13. European Society of Hypertension-European Society of Cardiology Guidelines Committee 2003 European society of hypertension-European society of cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21(6):1011-53. https://doi.org/10.1097/00004872-200306000-00001
14. Neutel JM, Frishman WH, Oparil S, Papademitriou V, Guthrie G. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther. 1999;6(3):161-6. https://doi.org/10.1097/00045391-199905000-00007 [Pubmed]   
15. Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens. 1999;17(2):293-302. https://doi.org/10.1097/00004872-199917020-00015 [Pubmed]   
16. Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2014;8:CD009096.
17. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-53.
18. Neutel J, Smith DH. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: Meta-analysis of a clinical database. J Clin Hypertens (Greenwich). 2003;5(1):58-63. https://doi.org/10.1111/j.1524-6175.2003.01612.x
19. Neutel JM. Use of ambulatory blood pressure monitoring to evaluate the selective angiotensin II receptor antagonist, telmisartan, and other antihypertensive drugs. Blood Press Monit. 2000;5 Suppl 1:S35-40.
20. Williams B, Lacourcière Y, Schumacher H, Gosse P, Neutel JM. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: A pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens. 2009;23:610-9. https://doi.org/10.1038/jhh.2009.4 [Pubmed]   
21. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59. https://doi.org/10.1056/NEJMoa0801317 [Pubmed]   

This Article Cited By the following articles

A Prospective Comparative Study of Efficacy and Pleiotropic Effect of Telmisartan versus Enalapril in Hypertensive Patients with Dyslipidaemia in a Tertiary Care Hospital in Visakhapatnam
jebmh 2021; 8(23): 1915.

1
 

2018; (): 243.

2
 
How to Cite this Article
Pubmed Style

Mustafa Raja, Ajay Kumar Shukla, Rekha Mehani, Astha Agnihotri. Comparative study of telmisartan and ramipril as an antihypertensive in mild to moderate hypertension. Natl J Physiol Pharm Pharmacol. 2016; 6(5): 388-393. doi:10.5455/njppp.2016.6.0409001052016


Web Style

Mustafa Raja, Ajay Kumar Shukla, Rekha Mehani, Astha Agnihotri. Comparative study of telmisartan and ramipril as an antihypertensive in mild to moderate hypertension. https://www.njppp.com/?mno=221737 [Access: December 01, 2022]. doi:10.5455/njppp.2016.6.0409001052016


AMA (American Medical Association) Style

Mustafa Raja, Ajay Kumar Shukla, Rekha Mehani, Astha Agnihotri. Comparative study of telmisartan and ramipril as an antihypertensive in mild to moderate hypertension. Natl J Physiol Pharm Pharmacol. 2016; 6(5): 388-393. doi:10.5455/njppp.2016.6.0409001052016



Vancouver/ICMJE Style

Mustafa Raja, Ajay Kumar Shukla, Rekha Mehani, Astha Agnihotri. Comparative study of telmisartan and ramipril as an antihypertensive in mild to moderate hypertension. Natl J Physiol Pharm Pharmacol. (2016), [cited December 01, 2022]; 6(5): 388-393. doi:10.5455/njppp.2016.6.0409001052016



Harvard Style

Mustafa Raja, Ajay Kumar Shukla, Rekha Mehani, Astha Agnihotri (2016) Comparative study of telmisartan and ramipril as an antihypertensive in mild to moderate hypertension. Natl J Physiol Pharm Pharmacol, 6 (5), 388-393. doi:10.5455/njppp.2016.6.0409001052016



Turabian Style

Mustafa Raja, Ajay Kumar Shukla, Rekha Mehani, Astha Agnihotri. 2016. Comparative study of telmisartan and ramipril as an antihypertensive in mild to moderate hypertension. National Journal of Physiology, Pharmacy and Pharmacology, 6 (5), 388-393. doi:10.5455/njppp.2016.6.0409001052016



Chicago Style

Mustafa Raja, Ajay Kumar Shukla, Rekha Mehani, Astha Agnihotri. "Comparative study of telmisartan and ramipril as an antihypertensive in mild to moderate hypertension." National Journal of Physiology, Pharmacy and Pharmacology 6 (2016), 388-393. doi:10.5455/njppp.2016.6.0409001052016



MLA (The Modern Language Association) Style

Mustafa Raja, Ajay Kumar Shukla, Rekha Mehani, Astha Agnihotri. "Comparative study of telmisartan and ramipril as an antihypertensive in mild to moderate hypertension." National Journal of Physiology, Pharmacy and Pharmacology 6.5 (2016), 388-393. Print. doi:10.5455/njppp.2016.6.0409001052016



APA (American Psychological Association) Style

Mustafa Raja, Ajay Kumar Shukla, Rekha Mehani, Astha Agnihotri (2016) Comparative study of telmisartan and ramipril as an antihypertensive in mild to moderate hypertension. National Journal of Physiology, Pharmacy and Pharmacology, 6 (5), 388-393. doi:10.5455/njppp.2016.6.0409001052016